- cafead   Jul 31, 2018 at 07:12: PM
via Pfizer has culled Type 1 diabetes and cancer drugs from its early-phase pipeline (PDF). The actions affect anti-IL7R antibody PF-06342674 and third-generation, mutant-selective EGFR tyrosine kinase inhibitor PF-06747775.
article source
article source